Overview

Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Continued smoking after a cancer diagnosis has important health consequences beyond the risks associated with smoking in the general population. Smoking reduces the efficacy of cancer treatments including surgery, radiation and chemotherapy. Despite the negative consequences, it is estimated that between 15-75% of patients with cancer continue to smoke after their cancer diagnosis. Lung, breast, prostate, colorectal, bladder, head & neck, and cervical cancer patients were chosen because there is evidence of potential clinical benefit associated with quitting smoking in all of these populations and they represent a mix of both smoking and non-smoking related cancers.
Phase:
Early Phase 1
Details
Lead Sponsor:
Wake Forest Cancer Center CCOP Research Base
Wake Forest University Health Sciences
Collaborator:
National Cancer Institute (NCI)
Treatments:
Nicotine